In this presentation from Lymphoma & Myeloma 2016, Dr. Sonali M. Smith discusses whether or not one should utilize cell of origin and “double protein” expression in the treatment of diffuse large b-cell lymphoma (DLBCL).
Click to Earn CME Credit: http://bit.ly/2mFKBrY
© 2016 Imedex, LLC.
Advertisement